Evidence map›Paper›PMID 37857690›Full record

ArticleNPJ biofilms and microbiomes2023

Selective inhibition of the amyloid matrix of Escherichia coli biofilms by a bifunctional microbial metabolite.

Estefanía Cordisco, María Inés Zanor, Diego Martín Moreno, Diego Omar Serra

Open access · goldAbstract read
In one paragraph

Article in NPJ biofilms and microbiomes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. DietaryAntibiotics (Basel, Switzerland) · 2026
    Article
  4. βProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Review
  6. Mechanical Comparison ofACS biomaterials science & engineering · 2025
    Article
  7. Antibiofilm Activities of Halogenated Pyrimidines Against EnterohemorrhagicInternational journal of molecular sciences · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Estefanía CordiscoLaboratorio de Estructura y Fisiología de Biofilms Microbianos, Instituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR), Predio CONICET Rosario, Ocampo y Esmeralda, (2000), Rosario, Argentina.ORCID 0000-0002-6574-1702
María Inés ZanorLaboratorio de Metabolismo y Señalización en Plantas, Instituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR), Predio CONICET Rosario, Ocampo y Esmeralda, (2000), Rosario, Argentina.ORCID 0000-0002-8903-0673
Diego Martín MorenoInstituto de Química Rosario (IQUIR, CONICET-UNR), Predio CONICET Rosario, Ocampo y Esmeralda, (2000) Rosario, Argentina. Facultad de Ciencias Bioquímicas y Farmacéuticas, Suipacha 531, (2000), Rosario, Argentina.ORCID 0000-0001-5493-8537
Diego Omar SerraLaboratorio de Estructura y Fisiología de Biofilms Microbianos, Instituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR), Predio CONICET Rosario, Ocampo y Esmeralda, (2000), Rosario, Argentina. dserra@ibr-conicet.gov.ar.ORCID 0000-0002-3926-384X
Consejo Nacional de Investigaciones Científicas y Técnicas · AR

Funding

Alexander von Humboldt-Stiftung (Alexander von Humboldt Foundation) Equipment grant Ref 3.4 - 8151/20 005
6 · The paper itself

Abstract

The propensity of bacteria to grow collectively in communities known as biofilms and their ability to overcome clinical treatments in this condition has become a major medical problem, emphasizing the need for anti-biofilm strategies. Antagonistic microbial interactions have extensively served as searching platforms for antibiotics, but their potential as sources for anti-biofilm compounds has barely been exploited. By screening for microorganisms that in agar-set pairwise interactions could antagonize Escherichia coli's ability to form macrocolony biofilms, we found that the soil bacterium Bacillus subtilis strongly inhibits the synthesis of amyloid fibers -known as curli-, which are the primary extracellular matrix (ECM) components of E. coli biofilms. We identified bacillaene, a B. subtilis hybrid non-ribosomal peptide/polyketide metabolite, previously described as a bacteriostatic antibiotic, as the effector molecule. We found that bacillaene combines both antibiotic and anti-curli functions in a concentration-dependent order that potentiates the ecological competitiveness of B. subtilis, highlighting bacillaene as a metabolite naturally optimized for microbial inhibition. Our studies revealed that bacillaene inhibits curli by directly impeding the assembly of the CsgB and CsgA curli subunits into amyloid fibers. Moreover, we found that curli inhibition occurs despite E. coli attempts to reinforce its protective ECM by inducing curli genes via a RpoS-mediated competition sensing response trigged by the threatening presence of B. subtilis. Overall, our findings illustrate the relevance of exploring microbial interactions not only for finding compounds with unknown and unique activities, but for uncovering additional functions of compounds previously categorized as antibiotics.

Indexed as

BiofilmsEscherichia coliAmyloidAmyloidogenic ProteinsAnti-Bacterial AgentsBacteriaPolyenesAmyloidAmyloidogenic ProteinsAnti-Bacterial AgentsbacillaenePolyenes

Identifiers

PMID37857690
PMCPMC10587114
OpenAlexW4387772743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.